Amphastar Pharmaceuticals, Inc.
AMPH · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 10% | 2.3% | -8.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 51.4% | 49.6% | 50% | 46.5% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 21.9% | 35.5% | 30.7% | 34.9% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 9% | 17.8% | 14.8% | 20.4% |
| EPS Diluted | 0.37 | 0.64 | 0.51 | 0.74 |
| % Growth | -42.2% | 25.5% | -31.1% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |